Home » Stocks » ATHE

Alterity Therapeutics Limited (ATHE)

Stock Price: $1.31 USD 0.01 (1.00%)
Updated Jul 29, 2021 11:22 AM EDT - Market open
Market Cap 55.67M
Revenue (ttm) 28,153
Net Income (ttm) -13.46M
Shares Out 40.11M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.31
Previous Close $1.30
Change ($) 0.01
Change (%) 1.00%
Day's Open 1.30
Day's Range 1.30 - 1.33
Day's Volume 297,959
52-Week Range 1.09 - 5.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatm...

2 weeks ago - PRNewsWire

MELBOURNE, Australia and SAN FRANCISCO , July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition o...

4 weeks ago - PRNewsWire

Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence...

1 month ago - PRNewsWire

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appoin...

3 months ago - PRNewsWire

Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. D...

3 months ago - Benzinga

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International...

5 months ago - PRNewsWire

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commer...

7 months ago - PRNewsWire

As of 1:46 PM ET, the stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) (ASX: ATH) is trading up 153.48% at $2.92 (up from the previous close of $1.15). Why is this happening?

8 months ago - Pulse2

Alterity Therapeutics (ATHE) news for Monday includes approval of a new patent protecting its drugs pushing ATHE stock higher. The post Alterity Therapeutics News: 8 Things for ATHE Stock Investors to K...

8 months ago - InvestorPlace

Shares of Alterity Therapeutics Ltd (NASDAQ: ATHE) gap-opened Monday's session higher and are sustaining the gains. What Happened: The Australian biopharma said the U.S. Patent and Trademark Office has ...

8 months ago - Benzinga

The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the Au...

8 months ago - Market Watch

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent b...

8 months ago - PRNewsWire

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients wit...

9 months ago - PRNewsWire

Alterity Therapeutics Ltd. (NASDAQ: ATHE) stock more than doubled on Tuesday after the company announced new data for its lead drug candidate ATH434.

11 months ago - 24/7 Wall Street

Shares of Alterity Therapeutics Ltd. ATHE, -7.53% nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present p...

11 months ago - Market Watch

The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.

11 months ago - Benzinga

Highlights: FDA provides guidance for ATH434 development pathway Company compliant with minimum NASDAQ price End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July ME...

11 months ago - PRNewsWire

Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.

1 year ago - Benzinga

Alterity Therapeutics Ltd. (NASDAQ: ATHE) says it has received an update from the U.S.

1 year ago - 24/7 Wall Street

About ATHE

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, A... [Read more...]

Industry
Biotechnology
Founded
1997
CEO
Geoffrey Kempler
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
ATHE
Full Company Profile

Financial Performance

Financial Statements